Drug Type Immunoglobulin |
Synonyms- |
Target- |
Mechanism Immunomodulators |
Therapeutic Areas- |
Active Indication- |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1997) |
Regulation- |
Phase 3 | 27 | bqkwxqljle(qeivrjeydl) = assessed as being related to the study drug fquswggwhb (tyufukqosg ) View more | Positive | 01 Feb 2021 | |||
Phase 3 | 486 | rHuPH20-enabled 10% IGSC infusions | doajszuesh(xbpcllnoxs) = Local adverse events (AEs) occurred in 16% of infusions. Most treatment-related AEs were mild and localized to the infusion site. iufvlizmou (jmtpuqiwcm ) View more | Positive | 01 Feb 2011 |